Evaluation of Pharmacokinetics, Safety, and Preliminary Efficacy of Isatuximab in Chinese Patients With Relapsed and/or Refractory Multiple Myeloma
NCT03733717
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
25
Enrollment
INDUSTRY
Sponsor class
Conditions
Multiple Myeloma
Interventions
DRUG:
Isatuximab SAR650984
Sponsor
Sanofi